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Research has been consistently showing the role of zinc (Zn) in prostate function. In
this article, we review the current literature on the anatomy and main functions of
the prostate, highlighting the role of zinc. In particular, we will review the etiology of
benign prostate enlargement (BPH), its prevalence in men over 50, the likelihood of BPH
becoming prostate cancer (PCa), and explain the relationship of zinc and apoptosis in the
prostate cells and the implications for BPH and PCa. We present a model that explains
how endogenous factors provoke excretion of zinc or limit zinc absorption, and how
exogenous factors like nutrition and drugs regularly used in men over 50 can significantly
decrease zinc status and thereby increase the risk of BPH. Finally, we explain how Zn
amino acid (AA) complexes may be capable of avoiding antagonists and inhibitors of
zinc absorption, thereby increasing the bioavailability of zinc for the necessary biological
processes in the prostate.
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INTRODUCTION
Anatomy and Function of the Prostate
The prostate is a gland located in the man’s pelvic cavity, behind the pubis. It is in front of the
rectum and under the bladder. It wraps and surrounds the first segment of the urethra just below
the bladder neck (Figure 1A).
The prostate is part of the urinary and reproductive system, anatomically related to other
structures such as the vas deferens and seminal vesicles. The glandular tissue of the prostate is
distributed in three histologically defined areas and immersed in several muscle layers, with little
presence of connective tissue, which ultimately creates three lobes: two lateral and one medium.
The anatomical model that is currently accepted distinguishes four zones in the prostate
(Figure 1B). The most critical areas with regards to prostate diseases are the central and peripheral
zones of the prostate. Almost all prostate carcinomas originate in the peripheral zone (1). The
anatomical characteristics favor that all the changes and pathological processes, both benign and
malignant, that occur in this gland cause more or less notable alterations in urination (2).
The primary function of the prostate gland as a male accessory sex organ lies in the
secretion of prostatic fluid, a component of semen that contributes between 15 and 30% of
overall seminal fluid volume (3). Through its smooth muscle layer, the prostate ensures that
the seminal fluid is pressed into the urethra during ejaculation (4). To prevent seminal fluid
from reaching the bladder during ejaculation, the prostate muscles and the urethral sphincter
contract effectively, closing off the urethra toward the bladder (3). The prostatic fluid contains
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FIGURE 1 | (A) Schematic representation of the location of the prostate (shown in red) in the male urogenital system. It is an organ of fibro-muscular and glandular
nature and has the shape of an inverted pyramid. (B) Four zones can be distinguished in the prostate: The anterior zone or fibromuscular stroma, the peripheral zone,
the central zone, and the transitional zone. The anterior zone is of fibromuscular nature, a thick sheet of compact connective and muscular tissue that covers the
entire anterior surface of the prostate. It surrounds the proximal urethra at the level of the bladder neck, where it joins the internal sphincter and detrusor muscle in
which it originates. It occupies almost a third of the total volume of the prostate and does not contain glands. It does not participate in any pathology of the prostate.
The peripheral zone is of endodermal origin and is the largest anatomical region of the glandular prostate. The central zone is the smallest of the regions of the
glandular prostate. It represents between 20 and 25% of its mass and is crossed by the ejaculatory ducts. The fourth zone, the transitional zone, has a mesodermal
origin, formed by a small group of ducts closely related to the proximal urethra. These ducts represent 5% of the glandular prostate mass.
various enzymes, citric acid, and high amounts of monovalent
and divalent metal ions such as zinc (3, 4).
Benign Prostate Hyperplasia (BPH)
Although the size of the prostate varies with age, in young and
healthy men, the normal gland size is about 3 × 3 × 5 cm
(25ml volume) and it weighs between 15 and 20 g. Usually,
this remains stable until men reach their 40’s, the age in which
a series of histological changes occurs: the gland grows and
blocks the urethra or bladder, causing difficulty in urinating
and interference in sexual functions that may eventually lead
to benign prostatic hyperplasia (BPH) (2, 5). BPH is defined by
histological alterations primarily within this prostatic transition
zone, characterized by the proliferation of the epithelium and
smooth muscle (6). According to McNeal (7), BPH develops
in two phases. Within the first 20 years of BPH development,
it is defined by an increase in the number of BPH nodules,
while during the second phase, BPH is primarily characterized
by an increase in the size of glandular nodules (7, 8). Problems
for patients can arise in two ways, by direct bladder outlet
obstruction (BOO) due to size of the enlarged prostate (static
component) or by an increase in smooth muscle tone within the
prostate (dynamic component), potentially manifesting in lower
urinary tract symptoms (LUTS) (6, 9, 10). BPH is a common
age-related phenomenon in men. While half of the men in their
60 s (50–60%) develop hyperplasia, by the time men reach the
age of 70 and 80 years of age, 80–90% are affected (11, 12).
Although not every man with BPH will necessarily be affected
by significant LUTs, most common complaints include weak
urine flow, straining, hesitancy, pro-longed voiding, complete or
partial retention of urine, overflow incontinence of the bladder or
irritative symptoms such as nocturia, painful urination and urge
incontinence (12).
Transformation of Normal Prostate to BPH:
BPH as a Precursor of Prostate Cancer
(PCa)
While the development of BPH is not yet completely understood,
the etiology appears to be under endocrine control and
multifactorial (13). Common consensus explains the volumetric
increase of the prostate gland due to reduced apoptosis and
cellular hyperplasia. This theory is defined as the “primordial
cell” theory (14).
The development of BPH often begins around 40 years of age
with a focal phenomenon of stromal origin. From the age of 50,
there is then a global and rapid increase in volume due to an
increase in the number of fibromuscular and glandular tissue
cells, both in the periurethral and transitional areas. Thus, the
increase in prostate volume is caused by excessive cell growth
and a limited process of apoptosis, caused by the imbalance of
growth-promoting factors and that of inhibitors, manifesting as
pathology. Thereby, the leading causes of cell growth are:
Testosterone and Dihydrotestosterone (DHT): Within the
prostate, the hormone testosterone is converted to DHT
by 5-alpha reductase. Besides stimulating prostate growth
and development, DHT seems to be instrumental in the
progression of BPH pathology (9). While increased serum
concentrations of testosterone itself seem not to increase the
risk of developing BPH, several studies report that increased
levels of DHT or DHT metabolites (17b-diol-glucuronide,
androstanediol glucuronide) promote BPH (9, 15, 16). In line
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with these findings, medical intervention in the form of 5-
alpha reductase inhibitors (finasteride and dutasteride) for
treatment of BPH and resulting LUTS hinders the further
progression of BPH, by decreasing DHT concentration in serum
of patients (9, 17, 18).
Lifestyle
Besides endocrine factors such as DHT, lifestyle factors, especially
those associated with metabolic abnormalities connected to
cardiovascular disease, pose a risk for developing prostatic
diseases such as BPH and prostate cancer. These factors lead
to the so-called metabolic syndrome, which includes glucose
intolerance, hypertension, and obesity (9, 19).
Prostate cancer (PCa), as the second most diagnosed type
of cancer in men and BPH with a majority of men afflicted
at an older age, show commonalities on the genetic, molecular,
and cellular level. This suggests an association of BPH with
prostate cancer development, if not causality (20). Due to
the similarities in pathogenesis and the role of androgens in
growth, antiandrogenic drugs, 5-alpha reductase inhibitors, and
gonadotropin-releasing hormone agonists are useful for the
treatment of both BPH and PCa (20–22). However, although
BPH has been suggested to be a risk factor for PCa, which
has been confirmed in a meta-analysis (23), the underlying
mechanisms that may explain a causal link in the relationship
between BPH and PCa are currently not well-known (24).
In addition, another study proposed that BPH may actually
slow down tumor formation by mechanically impeding tumor
growth (25).
BOO and BPH, when associated with LUTS, impact public
health considerably (9). A study reports 3.7 million emergency
room visits within 3 years (2007 to 2010) by men in the US due
to urinary retention (9, 26, 27). With an increasing incidence
rate of BPH and associated complications, public health costs for
diagnosis and treatment are substantial. Estimates of the annual
cost for provided health care services within the US for BPH
treatment range around $3.9 billion in 2014 and might be much
higher to date (9).
DISCUSSION
The Role of Zinc in Normal Prostate
Function and Metabolism
To produce and secrete high levels of citrate, the prostate
accumulates high levels of zinc in specialized acinar epithelial
cells of the peripheral zone. Zinc levels and citrate metabolism
are linked in the prostatic gland. Zinc inhibits mitochondrial
aconitase (28). M-aconitase is responsible for the catalyzation
of the oxidation of citrate to isocitrate as part of the first
step in the Krebs cycle. The inhibitory effect of zinc results
in the accumulation of citrate in the mitochondria before it is
exported to the cytosol and secreted as a major component of
prostatic fluid (29). Thus, the high levels of zinc in the prostate
ensure the inhibition of M-aconitase while zinc that occurs
outside the prostate in lower levels cannot act as a competitive
inhibitor (29–31). The zinc transporter ZIP1 (Zrt- and Irt-like
proteins 1, SLC39A1) is responsible for the uptake of zinc into
prostate cells. The upregulation of ZIP expression in prostate
cells ensures the accumulation of zinc in the prostate (29)
(Figure 2A), a process that may be regulated by testosterone and
prolactin (32).
Besides its role in the truncation of the Krebs cycle resulting in
decreased energy production in the prostate and release of high
levels of citrate in prostatic fluid, zinc accumulation in prostate
cells can be an inducer of mitochondrial apoptosis, thereby
effectively inhibiting proliferation and growth of the tissue
(33). In in vitro studies, non-zinc-accumulating prostatic cells
do not show apoptogenic properties, while zinc accumulating
cells exhibit these capabilities suggesting that apoptogenesis is
a unique feature of zinc accumulating prostate cells (33). Zinc
hereby is taken up into the mitochondria of the prostate causing
cytochrome c to be released from the mitochondria, triggering
caspase activation and the induction of apoptosis (Figure 2A).
Intriguingly, both zinc and citrate are diminished in prostate
cancer, implicating an essential role of high zinc levels for
maintaining a non-malignant prostate.
Zinc Deficiency in Prostate Disease
More than 16 studies have reported that zinc is markedly
decreased (∼60–80%) in prostate cancer compared to normal
and benign prostate tissue and no study reported prostate cancer
without decrease in zinc levels so far (32).
High levels of zinc are essential for maintaining prostate
health and function due to its role in apoptosis and truncation
of the Krebs cycle (citrate accumulation) (34). While this unique
metabolic process in prostate cells ensures high levels of citrate
release in the prostatic fluid as a major component in semen, it
negatively affects the process of energy generation. Hence, when
prostate cells undergo malignancy, and cancerous cells lose their
capability to accumulate zinc, the continuation of the Krebs cycle
releases energy, making malignant cell growth in the prostate
more energy-efficient for the cells (35–37).
Taking this into consideration, insufficient zinc levels might
have troublesome repercussions for men. Indeed, in prostate
cancer tissue, mean zinc levels are decreased by up to 80%,
and in prostatic tissue derived from BPH, zinc levels are
decreased by more than 50% (38). In addition, a significant (on
average, 44%) increase was observed in the urine zinc/creatinine
levels in prostate carcinoma when compared to BPH, and a
highly significant increase (on average, 53%) when compared
with controls was found, hinting at increased zinc excretion.
There was also already a significant increase in urine zinc
excretion in men with BPH compared to men with a healthy
prostate. This suggests that pathological conditions of the
prostate gland in patients with BPH or carcinoma may be
associated with an alteration in biochemical parameters such
as a reduction in the level of tissue zinc, plasma zinc, and
an increase in urinary zinc excretion (38). For example, a
recent study found that PCa patients had markedly reduced
plasma zinc levels and that a low zinc status was more
pronounced within the severe grade and advanced PCa disease
subgroups, suggesting that low zinc status is associated with
PCa (39).
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FIGURE 2 | (A) Prostate cells accumulate high levels of zinc. Zinc enters the mitochondria causing cytochrome c to be released from the mitochondria, triggering
caspase activation and the induction of apoptosis (left panel). Alternatively, zinc can inhibit aconitase, the enzyme catalyzing the production of isocitrate from citrate in
the Krebs cycle (right panel). This leads to the accumulation of high levels of citrate that is characteristic for prostate cells. (B) The concept of the oncogenetic and
genetic/metabolic transformations in the carcinogenesis process, and the role of zinc and zinc transporters in the etiology of prostate cancer. Premalignant cells may
have predisposing mutations in tumor genes. A decrease in zinc and/or decrease in the ZIP1 transporter in prostate cancer occur as early events in premalignant cells
and precede malignancy. Zinc deficiency and/or the downregulation of zinc import proteins subsequently results in a malignant cell.
Hypothesis: Low Zinc Status Is the
Possible Cause of Both BPH and PCa
Pieces of evidence have accumulated that support this hypothesis:
Costello and Franklin (37) proposed “a modified concept
of the carcinogenesis process that incorporates a multistep
oncogenetic transformation of normal cells to neoplastic cells,
and genetic/metabolic transformation of the neoplastic cells to
premalignant cells and ultimately tomalignant cells” (Figure 2B).
In this concept, a key role of zinc in the transformation
process was proposed. A decrease in zinc levels does not
necessarily trigger malignancy without an initial oncogenetic
transformation from the normal state to a neoplastic state with
malignancy potential. However, a decrease in zinc levels and/or
downregulation of ZIP1 will facilitate the transformation from
a neoplastic cell with malignant potential to a malignant cell.
This ZIP1/loss of zinc transformation occurs in almost all cases
of prostate cancer. The downregulation of ZIP1 may be linked
to abnormal REBB-1 (ras responsive binding element protein-1)
function. REBB-1 is a transcription factor regulating ZIP1 gene
expression and its activity is controlled by RAS. Unfortunately,
RREB-1 regulation via RAS signaling remains poorly understood
and the involved genes/signaling pathways await identification
(40, 41).
Due to zinc’s role as a stepping stone in developing malignant
cells, restoration of normal zinc levels may be a promising
approach in prostate cancer prevention and treatment (28). In
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addition, decreased levels of zinc may lead to an increased
activation of the ZnR/GPR39 receptor in prostate cancer cells.
ZnR/GPR39 is a plasma membrane G-protein coupled receptor
that is sensitive to zinc. ZnR/GPR39 activation in prostate cancer
cells was shown to promote cell growth through PI3K dependent
upregulation of ERK and AKT phosphorylation (42). However,
following ZnR/GPR39 desensitization, ERK phosphorylation
was diminished in prostate cancer cells (43). ZnR/GPR39
desensitization can be achieved through the presence of
physiological concentrations of zinc and citrate (43). Thus,
restoration of zinc levels and, thereby, prevention of low citrate
concentrations, together, may prevent ZnR/GPR39 mediated
enhancement of prostate tumor growth.
The decrease in zinc, along with the corresponding decrease
in citrate levels, is the most consistent and persistent existing
hallmark characteristic that differentiates prostate cancer from
normal and benign prostate.
The Prevalence of Low Zinc Status in Men
Over 50 and Its Endogenous and
Exogenous Causes: A Need for Zinc
Supplementation?
In the light that more than half of men in their 60’s suffer
from BPH, which increases to 90% by 70–80 years of age, and
the direct effects of zinc on normal or malignant prostate cells,
the need of adequate zinc status in men for having a healthy
prostate becomes evident. Prostate zinc levels are depending
on circulating zinc concentrations that have to be considered
(29), which puts a focus on maximizing cellular uptake of zinc
in tissues and absorption of zinc in the intestines. It has been
shown in several studies that older adults (older adults >50
years) frequently have low zinc status (44, 45). Although the
daily requirement for zinc does not increase with age, lifestyle
factors and a reduced capacity to absorb zinc, an increase in
the likelihood of diseases that affect zinc utilization, and the use
of drugs that may decrease the bioavailability of zinc may all
contribute to putting older individuals at an increased risk for
the development of a mild zinc deficiency (Table 1).
Older adults that are vulnerable to the onset of BPH
and PCa, therefore, may need zinc supplementation. Men
with BPH and PCa have an increase in zinc excretion
compared with healthy men (38); at the same time, some
comorbidities are also known to provoke zinc excretion such
as severe or persistent diarrhea, inflammatory bowel diseases,
and renal disease. Recent studies and meta-analyses have
found an association between inflammatory bowel disease and
PCa (92–94). Besides, endogenous factors that prevent zinc
absorption are more frequently present in older men, such as
malabsorption syndromes (e.g., celiac disease and short bowel
syndrome), and GI cancers.
Besides these endogenous factors, exogenous factors can
lead to lower zinc status in older adults, such as limited food
choices leading to a less variable diet that may include dietary
factors that lower the bioavailability of zinc, or that are low in
zinc content. For example, the evaluation of zinc intakes using
dietary reference intakes, recommended dietary allowances, and
estimated average requirements for elderly adults (60 years and
older) showed that the prevalence of inadequate dietary intake
zinc was 35–41% for males, and 36–45% for females (44).
The requirement for dietary zinc may be as much as 50%
greater for individuals on a vegetarian diet whose major food
staples are grains and legumes because high levels of phytate in
these foods reduce zinc absorption (44, 95).
Phytic acid (PA) binds zinc in the gastrointestinal tract,
thereby diminishing the bioavailability of zinc (66–68, 96). In
addition, various other factors can influence zinc absorption. For
example, drug interactions with zinc may decrease its absorption
or provoke its excretion. A widely used drug is omeprazole, used
for the treatment of acid reflux disease by decreasing stomach
acid levels. According to a study, patients taking omeprazole
showed a marked increase of zinc deficiency (from 16 to 50%
within 2 months) upon starting treatment with the drug (58).
Besides proton-pump inhibitors, chelating drugs used to treat
metal toxicity (like diethylenetriamine pentaacetate used in the
treatment of iron overload and penicillamine prescribed to treat
the copper overload in Wilson’s disease) cause serious side
effects in the form of severe zinc deficiency (80). Additionally,
anticonvulsant drugs, such as sodium valproate and constant
usage of diuretics, may negatively affect zinc levels in patients.
Few studies investigated the effects of zinc supplementation
so far. For example, a study reported a protective role for zinc
in BPH (97). In addition, the accumulation of zinc in prostate
tissue depends on the activity of zinc transporters such as ZnT4
(SLC30A4) and ZIP4 (SLC39A4) that can be modulated by
nutraceuticals such as daidzein. A combination of zinc, daidzein
and isolase improved clinical symptoms and quality of life in
patients with LUTS due to BPH (98, 99)
Supplementing Zinc for Maintaining
Adequate Zinc Levels in Older Men: Not All
the Sources of Zinc Are Alike
Taken together, more than 50% of men over 60 suffer from BPH,
and also have low zinc status. Thus, there is a strong case for
establishing a program of zinc supplementation in men over 50
due to the endogenous and exogenous factors presented above.
Several studies showed that the treatment of malignant prostate
cells with zinc that will increase cellular zinc levels leads to
the inhibition of cell proliferation, promotion of apoptosis, and
inhibition of cell migration and invasion (28). However, there
are many options available for supplementation, and choosing
the correct supplement may be critical to achieving effects in
prostate tissues.
Not all sources of zinc deliver the metal to the body for
utilization in the same way. Ionic zinc (Zn2+) from dietary
sources is taken up in the intestine by the ZIP family of zinc
transporters, transporting zinc from the gut lumen into the
intestinal enterocytes. From the enterocytes, zinc is further
transported into the bloodstream by another family of zinc
transporters, the ZnT transporter family (100). As described
above, there are many antagonists and drug-interactions that
can inhibit the uptake and utilization of ionic zinc. Therefore,
inorganic zinc (Zn2+) sources may not be the best choice for
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TABLE 1 | Summary of endogenous and exogenous factors that may contribute to low zinc status in older men.






Severe or persistent diarrhea
(46, 47)
Malabsorption syndromes (48),
celiac disease (49–53), and short
bowel syndrome (54)
Lack of Zn intake in the elderly
due to restricted food choices
and patterns (55–57)




including Crohn’s disease and
ulcerative colitis (61–65)
Gastrointestinal cancers Presence of dietary factors that
influence zinc absorption. E.g.,
Phytic acids (66–71)
Medications like tetracycline and
quinolone antibiotics (72–74)
Alcoholic liver disease (75–79) Metal-chelating agents, such as
penicillamine, diethylenetriamine
pentaacetate (DTPA) (80–83)
Chronic renal disease (84–87) Anticonvulsant drugs (sodium
valproate) (88–91)
older men. As an alternative, many forms of organic ligands for
zinc are available for human use. Common ones are citrates,
gluconates, glycinates, and picolinate. Careful consideration
should be given to the viability of the chemistry. If the ligand
dissociates due to the low pH in the stomach, the supplement
will effectively behave like an inorganic metal supplement. If the
ligand stays bound, but the complex is not absorbed well, the
delivered zinc will not become bioavailable.
Our recent studies show that certain amino acids used as
ligands are promising for delivering the metal (69). Amino acids,
for example, from digested proteins, are taken up by at least
four sodium-dependent amino acid transporters, and sodium-
independent transporters, mediating the uptake of acidic, basic,
and neutral amino acids. It was found that the metal bonded
to the amino acids (Zn-AA) can be transported through the
amino acid transporter and, therefore, may not be affected by
the absence of plasma membrane localized ZIP1 transporter in
the malignant PCa cells. We recommend the combination of
zinc bound to glutamate (Glu) and lysine (Lys). This has been
determined to be an advantageous combination for both uptake
into the enterocyte as well as the passage into the circulation (69).
The Lys and Glu, in combination, utilize different transporters.
It has also been determined that metal amino acid complexes
are not affected by common antagonists the same way inorganic
supplements are (69). Furthermore, once in the circulation,
amino acid complexes are excreted at a slower rate than other
sources of minerals. Methionine (Met) is another viable option
being an essential amino acid butmainly utilizing only one amino
acid transporter. Methionine complexes have been patented in
the early 1970’s (Pat. No. US3941818A) and are still available for
the use in humans.
The way of cellular uptake and the protection from
sequestering by metallothionines, as well as slower excretion
profiles may give organic zinc supplements such as ZnAAs
an advantage that could be especially beneficial for older
individuals. In particular, because older individuals may have
restricted dietary habits with nutrients low in zinc or with high
concentrations of uptake antagonists. In addition, medications
that are taken and that limit zinc availability may be less
disruptive for ZnAAs. Besides, metallic amino acid complexes
have been used as human supplements and have a long history
of safety and efficacy. They are frequently used as a mineral
supplement for animals, where extensive research data shows
their effectiveness and advantages over inorganic supplements.
CONCLUSIONS
The decrease in zinc and, subsequently, citrate levels is the most
characteristic hallmark of prostate cancer. The important role
of zinc as a regulator of apoptosis in prostate cells makes the
decrease a likely cause for rather than a consequence of PCa.
Therefore, an adequate dietary intake of zinc is essential for older
adults. The consequences of only mild zinc deficiency, such as
impaired immune system function, are especially relevant to the
maintenance of health and may be critical in the prevention
of age-related diseases. Especially in the prostate, adequate zinc
status will help to maintain health and physiological function and
prevent prostate disease from developing or further progressing,
thereby acting as a vital anti-BPH and anti-PCa agent. Thus,
targeted zinc supplementation with supplements tailored to the
needs of the elderly, i.e., ZnAAs, should be considered.
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